Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors

<p>Supplementary Figure 1: Characterization of INX-315.Supplementary Figure 2: Effect of INX-315 and PF-07104091 on viability of cancer and non-malignant cell lines.Supplementary Figure 3: Effect of INX-315 on cell cycle in CCNE1-amplified cancer cell lines.Supplementary Figure 4: Further characterization of the effects of INX-315 in in vitro and in vivo models of CCNE1-amplified cancer.Supplementary Figure 5: Effects of INX-315 treatment on gene expression in models of CCNE1amplified ovarian carcinoma.Supplementary Figure 6: Characterization of CDK4/6 inhibitor-resistant cell lines.Supplementary Figure 7: Response of CDK4/6 inhibitor-resistant breast cancer cells to INX-315 and PF-07104091.Supplementary Figure 8: Effects of INX-315 and PF-07104091 on CDK4/6 inhibitor-resistant breast cancer cells.Supplementary Figure 9: Impact of INX-315 +/- continued CDK4/6 inhibition in CDK4/6 inhibitorresistant breast cancer cells.Supplementary Figure 10: Characterization of a new mouse model of acquired CDK4/6 inhibitor resistance.Supplementary Figure 11: Effect of INX-315 on expression of senescence-related genes in CDK4/6 inhibitor-resistant breast cancer cells.Supplementary Figure 12: Epigenomic and transcriptomic features of INX-315 induced senescence in CDK4/6 inhibitor-resistant breast cancer.Supplementary Figure 13: Impact of INX-315 treatment of CDK4/6 inhibitor resistant breast cancer on expression of apoptosis and differentiation-related genes.Supplementary Figure 14: Impact of co-inhibition of CDK2 and CDK4/6 on cell cycle and development of CDK4/6 inhibitor resistance in breast cancer cells.</p>